Continuation is covered when the member achieves or maintains a positive clinical response as defined per indication:
RA continuation: Achievement or maintenance of ≥20% improvement from baseline in tender joint count, swollen joint count, pain, or disability
JIA continuation: For members ≥2 years: low disease activity or improvement in number of active joints, number of joints with limitation, or functional ability
PsA continuation: Low disease activity or improvement in swollen/tender joints, dactylitis, enthesitis, axial disease, or skin/nail involvement
AS/nr-axSpA continuation: Low disease activity or improvement in functional status, total spinal pain, or inflammation (e.g., morning stiffness)
CD continuation: Remission OR improvement in abdominal pain, diarrhea, body weight, abdominal mass, hematocrit, mucosal appearance on imaging/endoscopy, or CDAI score
UC continuation: Remission OR improvement in stool frequency, rectal bleeding, urgency, CRP, fecal calprotectin, mucosal appearance on imaging/endoscopy, or disease activity scoring tool (e.g., UCEIS, Mayo); note: continue only if clinical remission by 8 weeks for UC induction
PsO continuation: Reduction in BSA or improvement in signs/symptoms (itching, redness, scaling) compared with baseline
HS continuation: Reduction in abscess/inflammatory nodule count, fewer sinus tracts, decreased lesion frequency, reduced pain/suppuration, improved QoL or disease severity score
Uveitis continuation: Reduced flare frequency, stability/improvement in AC cell grade, VH grade, visual acuity, reduction in glucocorticoid requirements, and no new active retinal/chorioretinal lesions
ICI-toxicity continuation: Achievement or maintenance of low disease activity or improvement in signs and symptoms of immunotherapy‑related inflammatory arthritis